Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.52 |
| ▸ | CES1 | P23141 | 3/20 | 0.52 |
| ▸ | PDE2A | O00408 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15853708 | 1.00 | CES2 (0.52) | CES2CES1PDE2AMEN1KMT2A | |
| SCHEMBL29453648 | 1.00 | CES2 (0.52) | CES2CES1PDE2AMEN1KMT2A | |
| SCHEMBL17947416 | 1.00 | CES2 (0.52) | CES2CES1PDE2AMEN1KMT2A | |
| SCHEMBL24938981 | 0.84 | PDE2A (0.61) | CES2CES1PDE2AMEN1KMT2A | |
| SCHEMBL31621826 | 0.83 | CES2 (0.49) | CES2CES1PDE2AMEN1KMT2A | |
| SCHEMBL15854160 | 0.82 | CES2 (0.52) | CES2CES1PDE2AMEN1KMT2A | |
| SCHEMBL31035929 | 0.82 | CES2 (0.52) | CES2CES1PDE2AMEN1KMT2A | |
| SCHEMBL265533 | 0.82 | CES2 (0.52) | CES2CES1PDE2AMEN1KMT2A | |
| SCHEMBL2016730 | 0.82 | CES2 (0.52) | CES2CES1PDE2AMEN1KMT2A | |
| SCHEMBL84105 | 0.81 | CES2 (0.46) | CES2CES1PDE2AIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | claimed |
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2023-01-26 | — | — | US | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| EP-4041727-B1 | ATF6 MODULATORS AND USES THEREOF | ALTOS LABS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | NXERA PHARMA UK LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250177397-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2024153946-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2024-07-25 | — | — | WO | disclosed |
| CN-111253404-B | Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof | 上海医药集团股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20040077699-A1 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6514978-B2 | Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-0714984-B1 | Process for producing optically active alcohol containing phenyl group | NISSHIN OIL MILLS LTD (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | LU TIANBAO (US) | 2001-09-13 | — | — | US | disclosed |
| EP-1086122-A1 | PYRAZINONE PROTEASE INHIBITORS | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (US) | 2001-03-28 | — | — | EP | disclosed |
| US-6204263-B1 | THROMBIN INHIBITORS. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| WO-1999064446-A1 | PYRAZINONE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5600027-A | Process for producing optically active alcohol containing phenyl group | THE NISSHIN OIL MILLS, LTD. (JP) | 1997-02-04 | — | — | US | disclosed |
| EP-0714984-A2 | Process for producing optically active alcohol containing phenyl group | The Nisshin Oil Mills, Ltd. (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, SNCA | CES2 2482/4885CES1 2450/4885PDE2A 1000/4885 |
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | CES2 1079/4885CES1 3417/4885PDE2A 385/4885 |
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | CES2 3697/4885CES1 4421/4885PDE2A 2001/4885 |
| US-20250177397-A1 | INHIBITORS OF MPTP | PARK7, PINK1, SNCA | CES2 1079/4885CES1 3417/4885PDE2A 385/4885 |
| US-20040077699-A1 | Substituted triazole diamine derivatives as kinase inhibitors | MAP2K2, PRKDC, MAP2K3 | CES2 3344/4885CES1 2839/4885PDE2A 3004/4885 |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | HPN, SERPINE1, SERPINC1 | CES2 1814/4885CES1 383/4885PDE2A 3119/4885 |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | ADORA1, ADORA3, OPRL1 | CES2 1394/4885CES1 1528/4885PDE2A 1485/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | CES2 1005/4885CES1 1662/4885PDE2A 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.